2 not yet recruiting, 2 recruiting, 1 suspended. 2 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Suspended 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow Primary Progressive Multiple Sclerosis (PPMS): new trials by email Literature Review of Primary Progressive Multiple Sclerosis (PPMS) trials Research Report on Primary Progressive Multiple Sclerosis (PPMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | AbelZeta Inc. | 119 | 2027-02-01 | 2026-10-13 |
| Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis. Online wellness course and online exercise platform, Usual Care Group - Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS) | Not applicable | Not yet recruiting | University of Iowa | 118 | 2026-11-15 | 2026-09-28 |
| A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) SUN-627, Placebo - Primary Progressive Multiple Sclerosis, Primary Progressive MS | Phase 2 | Recruiting | Sundance Biosciences, Inc. | 20 | 2026-10-01 | 2026-09-25 |
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
| Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis MRI, Neurocognitive examination for healthy subjects, blood sampling - Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS) | Recruiting | University Hospital, Basel, Switzerland | 300 | 2018-09-04 | 2024-12-16 |
Multiple Sclerosis, Chronic Progressive (5) · Multiple Sclerosis (4) · Demyelinating Diseases (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Fatigue (1) · Immune System Diseases (1) · Motor Activity (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Nervous System Diseases (1) · Neuroinflammatory Diseases (1)
Chronic Disease (5) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Autoimmune Diseases (4) · Autoimmune Diseases of the Nervous System (4) · Demyelinating Autoimmune Diseases, CNS (4) · Immune System Diseases (4) · Nervous System Diseases (4) · Demyelinating Diseases (3) · Behavior (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Inflammation (1) · Leukoencephalopathies (1)
Blood Specimen Collection (1) · Cyclophosphamide (1) · Interleukin-2 (1) · Mesna (1) · aldesleukin (1) · fludarabine (1) · ocrelizumab (1)
AbelZeta Inc. (1) · Indapta Therapeutics, INC. (1) · Sundance Biosciences, Inc. (1) · University Hospital, Basel, Switzerland (1) · University of Iowa (1)
United States (4) · Switzerland (1)
Cristina Granziera, Prof. Dr. med. (1) · Yihong Yao, PhD (1)
2018 (1)